Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. - Wikidata - thesis-toulmin - TriplyDB

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.

http://www.wikidata.org/entity/Q38087692

about

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept Development of gene and stem cell therapy for ocular neurodegeneration Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD.Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab.Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience.A novel peptide specifically binding to VEGF receptor suppresses angiogenesis and Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy

P2860

Q26786766-027512DD-669E-4BAD-85DD-1D273E5B919C Q28081549-EC7D9EE9-E27F-413D-BA42-B865378D94E1 Q35016867-86187A16-7000-4243-9929-0CA2C255BE34 Q36395332-EEF4EA66-547B-4AF3-8A86-264DE4CF83DA Q37003830-D69973D9-110F-4188-9657-96AFCA7B37A8 Q38874774-EA49B24E-94AE-495A-9AE3-D53628DE78DA Q41102546-06F88C6D-A5F7-4D69-A929-24D0CC65AA00 Q56890125-1EC8B77D-336A-48FA-BEB4-47E2FFF88369 Q58130274-902ACF4D-7DAB-4761-A0BF-071CCA4F523D

P2860

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.

http://www.wikidata.org/entity/Q38087692

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Aflibercept (VEGF Trap-Eye) fo ...... -related macular degeneration.

@en

type

label

Aflibercept (VEGF Trap-Eye) fo ...... -related macular degeneration.

@en

prefLabel

Aflibercept (VEGF Trap-Eye) fo ...... -related macular degeneration.

@en

P1433

Q38087692-476A3A9E-EC73-43C8-98D1-890A5AC3CA3D

P1476

Q38087692-A87D8BD0-FFF4-4EC8-BA9E-B045AC912079

P2093

Q38087692-E3019C54-488E-4BA6-9A32-52347E5A863A

P2860

Q38087692-0376AA93-B40D-467F-B4CB-FC49BC04B452

Q38087692-0A2244AB-89FF-490E-B53F-B966BAA1A66D

Q38087692-0A710544-1E63-458C-9DEE-1EFF9EEAC067

Q38087692-12B3833A-EA0A-4F4A-9AC6-6E2949A1640C

Q38087692-1CB77B2D-A9FE-4EB3-B22A-F26C67B7329B

Q38087692-1D1336B4-D177-482C-B2B1-93888D029B29

Q38087692-1DACDF68-DFEC-48F1-A4A1-E2C74BE4BC1E

Q38087692-30FF0AE1-CE0A-487A-A020-4F314C4664EB

Q38087692-38DF5166-69D7-4F29-A12D-DE04CC014677

Q38087692-3A583401-CE26-43A4-A661-E49A9E4050CF

P304

Q38087692-E0AC38DA-6BCE-4F69-BB10-3A6B137F1158

P31

Q38087692-4C47F93E-5B69-406F-AABA-617DE5219EFE

P356

Q38087692-6C843927-69AF-4DB5-8171-B3E6F5541A01

P407

Q38087692-D4DDCEC7-12D7-4341-B715-10D6E03083AF

P433

Q38087692-848DB760-1053-4FA5-90EB-94F6BFA20354

P478

Q38087692-3EA82A26-2C83-474F-99A4-11271BEC4DF7

P577

Q38087692-BABFBA5F-8DE7-4F8D-BBA3-734666E003DC

P698

Q38087692-0B330FE6-E179-4093-8674-85285B81E801

P356

P1433

Expert Review of Clinical Pharmacology

P1476

Aflibercept (VEGF Trap-Eye) fo ...... -related macular degeneration.

@en

P2093

Michael W Stewart

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

Vascular-specific growth factors and blood vessel formation

Ranibizumab for neovascular age-related macular degeneration

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

Human retinal molecular weight exclusion limit and estimate of species variation.

Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization.

Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial.

Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates.

P304

103-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECP.12.81

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23473589

http://www.w3.org/2001/XMLSchema#string